Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

about

The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Mantle Cell Lymphoma in the Thyroid: A Rare Presentation.

P2860

Q39029195-516A6311-A8B8-458E-8C2B-DE60905BC6ED Q49571214-5C17B3EB-8EB1-4111-A744-302DBB0328CB

P2860

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

Item

http://www.wikidata.org/entity/Q38805552

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

@en

type

Item

label

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

@en

prefLabel

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

@en

P1476

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

@en

P2093

Jia Ruan

http://www.w3.org/2001/XMLSchema#string

Peter Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

Mantle cell lymphoma: evolving management strategies

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

P2888

s11899-016-0324-3

P304

234-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0324-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009091539

http://www.w3.org/2001/XMLSchema#string

P698

27068437

http://www.w3.org/2001/XMLSchema#string

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

about

P2860

P2860

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698